Literature DB >> 26077925

Palliative surgical treatment for cutaneous metastatic tumor is a valid option for improvement of quality of life.

Hiroyuki Goto1,2, Toshikazu Omodaka1, Hiroto Yanagisawa1, Shusuke Yoshikawa1, Yuichi Yoshida2, Osamu Yamamoto2, Yoshio Kiyohara1.   

Abstract

A cutaneous metastatic tumor is relatively rare, and patients with such a tumor usually have a poor prognosis. Even if the metastases can be treated, the treatment cannot improve the prognosis. However, neglecting metastatic lesions sometimes results in a great deterioration of quality of life. Cutaneous metastatic foci are generally treated with chemotherapy and/or radiotherapy. On the other hand, surgical treatment is sometimes chosen for cutaneous metastases. In this study, we analyzed data for 40 patients with cutaneous metastatic tumors who received surgical treatment at Shizuoka Cancer Center between January 2009 and August 2014. Among these cases, lung cancer was the most common primary cancer and the craniocervical region was the most frequent metastatic site. Among the patients who died, the average duration to death after the operation was 186 days. We consider that resection of cutaneous metastatic tumors as palliative therapy is an appropriate therapeutic option if the patient's condition permits resection. Such treatment can improve quality of life for both the patients and their families.
© 2015 Japanese Dermatological Association.

Entities:  

Keywords:  cutaneous metastatic tumor; palliative therapy; prognosis; quality of life; surgery

Mesh:

Year:  2015        PMID: 26077925     DOI: 10.1111/1346-8138.12983

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  4 in total

Review 1.  Symptoms of and Palliative Treatment for Unresectable Skin Cancer.

Authors:  Hiroyuki Goto; Yoshio Kiyohara; Masahisa Shindo; Osamu Yamamoto
Journal:  Curr Treat Options Oncol       Date:  2019-03-27

2.  A single-centre experience of secondary cutaneous tumours with special reference to precocious metastases.

Authors:  Craig Wakefield; Orla McFeely; Cynthia Heffron
Journal:  Ir J Med Sci       Date:  2022-03-01       Impact factor: 1.568

3.  Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.

Authors:  Mario E Lacouture; Shari B Goldfarb; Alina Markova; Sant P Chawla; Karan Dewnani; Marc Iacobucci; Julie E Lang
Journal:  Breast Cancer Res Treat       Date:  2022-04-26       Impact factor: 4.624

Review 4.  Cutaneous metastasectomy: Is there a role in breast cancer? A systematic review and overview of current treatment modalities.

Authors:  Samantha Huang; Vishwas Parekh; James Waisman; Veronica Jones; Yuan Yuan; Nayana Vora; Richard Li; Jae Jung; Laura Kruper; Farah Abdulla; Yuman Fong; Wai-Yee Li
Journal:  J Surg Oncol       Date:  2022-04-07       Impact factor: 2.885

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.